Article info

Download PDFPDF
Randomised controlled trial
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

Authors

  1. Correspondence to Matthew Sherwood
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27710, USA; matthew.sherwood{at}duke.edu
View Full Text

Citation

Sherwood M, Piccini JP
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

Publication history

  • First published February 18, 2012.
Online issue publication 
September 20, 2012

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.